Surface Transforms witnessed a dramatic 98% drop in its share value this week after announcing that General Motors (GM) has opted to terminate their supply contract, which was initially set to continue until 2030.

This development poses a severe threat to the company’s future. In 2025, GM was responsible for 84% of Surface Transforms’ revenue, translating to £15.3 million in sales, and accounted for 85% of the brake discs sold by the company.

Since November 2024, GM has also supported Surface Transforms with £14.4 million in advance payments and operational assistance.

In a statement to the Stock Exchange, Surface Transforms disclosed that GM plans to switch its brake disc supply starting March 31, 2026. The company noted that they have yet to engage in direct discussions with GM regarding this abrupt decision, highlighting the unexpected nature of the contract termination.

The company’s leadership is taking swift action, announcing plans to engage with corporate restructuring advisers to safeguard stakeholder interests. This move clearly indicates that the company’s current structure may be at risk.

Specializing in carbon ceramic brakes for high-performance vehicles, Surface Transforms boasts technology that offers up to 70% weight reduction compared to traditional iron brakes. Despite the innovative product, the company’s heavy reliance on a single customer has left it vulnerable, especially now that GM has decided to sever ties.

The loss of General Motors as a customer, is ‘existential’ for Surface Tranforms

The wider picture

A turbulent week for global markets made its presence felt in the small-cap arena, with the AIM All-Share down 3.9% and below 800 for the first time since mid-January. For all that, it fared better than the FTSE 100, which fell 4.6%.

Aferian was among the casualties. Shares in the video streaming technology group were suspended from trading on AIM on Friday, down 37%, as it prepares for a potential administration process and the sale of its operating businesses.

Central Asia Metals fared little better, falling around 25% after the miner warned of a shorter lifespan for its Sasa zinc-lead operation in North Macedonia. 

A new life-of-mine plan will result in a non-cash impairment charge of up to $120 million. A comprehensive review of 2025 performance now puts Sasa’s mine life at 2034, five years shorter than previously envisaged, based on the Svinja Reka reserve and resource.

Galantas Gold

The week’s biggest riser, and one of the strongest performers of 2025 so far, is Galantas Gold. A 780% advance is remarkable by any measure, but what makes it more striking is that it traces back to a single announcement made on January 7 that the market has taken its time to fully absorb.

We touched on Galantas a few weeks ago when the stock first started moving. The story merits a closer look now.

The company holds small-scale projects in Omagh, Northern Ireland, and Gairloch, Scotland. But last November it made a pivot, shifting its focus to Chile, where its primary asset is the Indiana gold-copper mine.

Indiana sits in what geologists would consider elephant country, neighbouring globally recognised operations including Cerro Negro and Mantoverde.

The catalyst for this year’s move, though, appears to be the January 7 deal to acquire the Andacollo Oro gold project, a past-producing open-pit mine carrying a historical measured and indicated resource of 2 million ounces of gold, in a transaction worth more than $30 million. There is also a lower-confidence inferred resource of around 5 million ounces, which hints at the potential scale of the asset.

Being open-pit and at surface is key. The ore is easier and cheaper to extract than material sitting kilometres underground, meaning the capital costs of rehabilitation are likely to be substantially lower than restarting an underground operation. Set that against a gold price above $5,000 an ounce, and investor excitement starts to make a lot of sense.

Other movers

Union Jack Oil, down 62% over the past year, was buoyed by speculative buying that pushed the shares up 66% this week. 

For SkinBioTherapeutics shareholders, hobbled by accounting issues and the departure of its chief executive, there was some relief, with the stock up 59%. It is still down around 35%, however, since the revenue recognition problems first emerged. Meanwhile, on-market share buying by the company bidding to acquire Deltic Energy spurred that stock 50% higher.

For all the market’s breaking small- and mid-cap news, go to www.proactiveinvestors.co.uk

DIY INVESTING PLATFORMS

AJ Bell

AJ Bell

Easy investing and ready-made portfolios

Hargreaves Lansdown

Hargreaves Lansdown

Free fund dealing and investment ideas

interactive investor

interactive investor

Flat-fee investing from £4.99 per month

Freetrade

Freetrade

Investing Isa now free on basic plan

Trading 212

Trading 212

Free share dealing and no account fee

Affiliate links: If you take out a product This is Money may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting. This does not affect our editorial independence.

Compare the best investing account for you